MedicGo
Treatment of Patients With Non-Small-Cell Lung Cancer Harboring Rare Oncogenic Mutations.
Metadata
Journalclinical lung cancer3.55Date
2020 Jan 27
8 months ago
Type
Review
Journal Article
Volume
2020-Sep / 21 : 395-406
Author
Marmarelis ME 1, Langer CJ 2
Affiliation
  • 2. Division of Hematology & Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: [email protected]
Doi
PMIDMESH
Abstract
Non-small-cell lung cancer is a major cause of cancer morbidity and mortality worldwide, and these patients have traditionally had a grim prognosis. As our understanding of actionable molecular aberrations that drive oncogenesis has grown, so too has the number of available therapies with improved outcomes in selectively targeted patient populations. This review provides an overview of the clinical response of tumors harboring relatively rare oncogenic drivers to currently approved targeted agents and those in late-stage clinical development. Molecular testing methods available for screening for oncogenic drivers will be discussed.
Keywords: BRAF MET NTRK RET ROS1
Fav
Like
Download
Share
Export
Cite
3.5
Clin Lung Cancerclinical lung cancer
Metadata
LocationUnited States
FromCIG MEDIA GROUP, LP

No Data

© 2017 - 2020 Medicgo
Powered by some medical students